Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested ā papers, authors, and institutions outside the pilot are not represented. Methodology.
Driven by 1 paper. Top paper: āUS Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone ReceptorāPositive, Human Epidermal Growth Factor Receptor 2āNegative Locally Advanced or Metastatic Breast Cancer With PIK3CA / AKT1 / PTEN Alterationsā.
James Buturla, Christy Osgood, Xin Gao, Wei Chen, Tiffany K. Ricks +14 more